| Title |
Clinical Studies on the Efficacy of Agomelatine on Depressive Symptoms
|
|---|---|
| Published in |
CNS Drugs, August 2012
|
| DOI | 10.2165/11318650-000000000-00000 |
| Pubmed ID | |
| Authors |
Guy M. Goodwin |
| Abstract |
The novel mechanism of action of agomelatine, with affinity for melatonergic and 5-HT(2C) receptors, offers the prospect of efficacy in major depression and anxiety with minimal adverse effects. The challenge of performing acute placebo-controlled treatment trials in a relevant sample of patients with moderate to severe major depression is considerable. The efficacy of active treatment may be obscured by excessive responses in placebo and active treatment arms. The agomelatine programme has successfully introduced methodological innovation to overcome this risk and ensure that cases of major depression display adequate severity on both ratings of symptoms and measures of functional impairment. The efficacy of agomelatine in major depression has thus been demonstrated at doses of 25-50 mg against the full range of symptoms that make up the depressive syndrome in patients with moderate to severe major depression. |
Mendeley readers
The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 21 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Doctoral Student | 4 | 19% |
| Researcher | 3 | 14% |
| Student > Postgraduate | 2 | 10% |
| Student > Master | 2 | 10% |
| Lecturer | 1 | 5% |
| Other | 4 | 19% |
| Unknown | 5 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 38% |
| Agricultural and Biological Sciences | 3 | 14% |
| Nursing and Health Professions | 1 | 5% |
| Psychology | 1 | 5% |
| Biochemistry, Genetics and Molecular Biology | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 7 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 October 2017.
All research outputs
#8,535,472
of 25,374,647 outputs
Outputs from CNS Drugs
#768
of 1,388 outputs
Outputs of similar age
#64,269
of 187,955 outputs
Outputs of similar age from CNS Drugs
#275
of 541 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,388 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,955 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 541 others from the same source and published within six weeks on either side of this one. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.